Donna R. Rivera

Donna R. Rivera

Auto-generated profile, based on publicly available information

Donna R. Rivera

Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DRDonna R. Rivera
Donna R. Rivera
SPSolange Peters
Solange Peters
OPOrestis A. Panagiotou
Orestis A. Panagiotou
DSDimpy P. Shah
Dimpy P. Shah
NKNicole M. Kuderer
Nicole M. Kuderer
JWJeremy L. Warner
Jeremy L. Warner
Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials.Significance: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.This article is highlighted in the In This Issue feature, p. 1426

29 December 2021 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
PDF file
LPLynne T. Penberthy
Lynne T. Penberthy
DRDonna R. Rivera
Donna R. Rivera
JLJennifer L. Lund
Jennifer L. Lund
MBMelissa A. Bruno
Melissa A. Bruno
AMAnne‐Marie Meyer
Anne‐Marie Meyer
Generating evidence on the use, effectiveness, and safety of new cancer therapies is a priority for researchers, health care providers, payers, and regulators given the rapid pace of change in cancer diagnosis and treatments. The use of real‐world data (RWD) is integral to understanding the utilization patterns and outcomes of these new treatments among patients with cancer who are treated in clinical practice and community settings. An initial step in the use of RWD is careful study design to assess the suitability of an RWD source. This pivotal process can be guided by using a conceptual model that encourages predesign conceptualization. The primary types of RWD included are electronic health records, administrative claims data, cancer registries, and specialty data providers and networks. Careful consideration of each data type is necessary because they are collected for a specific purpose, capturing a set of data elements within a certain population for that purpose, and they vary by population coverage and longitudinality. In this review, the authors provide a high‐level assessment of the strengths and limitations of each data category to inform data source selection appropriate to the study question. Overall, the development and accessibility of RWD sources for cancer research are rapidly increasing, and the use of these data requires careful consideration of composition and utility to assess important questions in understanding the use and effectiveness of new therapies.

25 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SSSonia Singh
Sonia Singh
DBDiana Bradford
Diana Bradford
XLXiaoxue Li
Xiaoxue Li
PMPallavi S. Mishra-Kalyani
Pallavi S. Mishra-Kalyani
YSYuan-Li Shen
Yuan-Li Shen
MDMartha Donoghue
Martha Donoghue
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.

23 August 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
MDMonica E. D'ARcy
Monica E. D'ARcy
DBDaniel C. Beachler
Daniel C. Beachler
RPRuth M. Pfeiffer
Ruth M. Pfeiffer
JCJeffrey R. Curtis
Jeffrey R. Curtis
XMXavier Mariette
Xavier Mariette
EEEric A. Engels
Eric A. Engels
Background: TNF inhibitors (TNFi) effectively treat rheumatoid arthritis but may increase patient risk of some malignancies, particularly lymphomas or skin cancers. Methods: We used Surveillance, Epidemiology, and End Results (SEER)–Medicare data to conduct a case–control study in patients with rheumatoid arthritis (2007–2015). Cases were individuals with a first cancer diagnosed in SEER registries (ages 66–99, 22 cancer sites, N = 10,263). Skin cancer cases [nonmelanoma skin cancer (NMSC, N = 501), basal cell carcinoma (BCC, N = 161), squamous cell carcinoma (SCC, N = 150)] and cancer-free controls (N = 30,475) were selected from Medicare beneficiaries residing in SEER areas. Cases and controls had prior Medicare claims-based evidence for rheumatoid arthritis, and TNFi exposure was ascertained from part B and part D claims. Logistic regression was used to estimate adjusted odds ratios (aOR). Results: TNFi exposure was present in 16.2% of controls and 12.8% to 33.7% of cancer cases, varying by site. TNFi use was associated with increased risk of NMSC overall (aOR 1.32, 95% confidence interval 1.06–1.63), non-Hodgkin lymphoma (NHL) overall (1.28, 1.06–1.56) and, specifically, follicular lymphoma (2.63, 1.63–4.24). TNFi exposure was not associated with other SEER cancer sites, BCC or SCC specifically, or other common NHL subtypes. Conclusions: Among older adults with rheumatoid arthritis, TNFi exposure was associated with elevated risk of NMSC and NHL, driven specifically by follicular lymphoma. Exposure was not associated with increased risk for other cancer sites. Impact: Our results support a role for TNF in lymphomagenesis. Given the association with NMSC, patients initiating TNFi therapy may benefit from skin cancer screening and sun protection measures.

10 December 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
AEArielle Elkrief
Arielle Elkrief
JWJulie Wu
Julie Wu
CJChinmay T. Jani
Chinmay T. Jani
KEKyle T. Enriquez
Kyle T. Enriquez
MGMichael Glover
Michael Glover
JWJeremy L. Warner
Jeremy L. Warner
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current or past history of cancer facing disparate consequences at every stage of the cancer trajectory. This comprehensive review offers a landscape analysis of the current state of the literature on COVID-19 and cancer, including the immune response to COVID-19, risk factors for severe disease, and impact of anticancer therapies. We also review the latest data on treatment of COVID-19 and vaccination safety and efficacy in patients with cancer, as well as the impact of the pandemic on cancer care, including the urgent need for rapid evidence generation and real-world study designs.Significance:. Patients with cancer have faced severe consequences at every stage of the cancer journey due to the COVID-19 pandemic. This comprehensive review offers a landscape analysis of the current state of the field regarding COVID-19 and cancer. We cover the immune response, risk factors for severe disease, and implications for vaccination in patients with cancer, as well as the impact of the COVID-19 pandemic on cancer care delivery. Overall, this review provides an in-depth summary of the key issues facing patients with cancer during this unprecedented health crisis.

17 January 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
DRDonna R. Rivera
Donna R. Rivera
MGMugdha N. Gokhale
Mugdha N. Gokhale
MRMatthew W. Reynolds
Matthew W. Reynolds
EAElizabeth B. Andrews
Elizabeth B. Andrews
DCDanielle Chun
Danielle Chun
SRSudha R. Raman
Sudha R. Raman